epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

Ann Intern Med

Study validates ultrasound-only approach to giant cell arteritis diagnosis

May 10, 2024

card-image

Among patients with high clinical suspicion of giant cell arteritis (GCA), positive findings on Doppler ultrasound of the temporal arteries meant that further diagnostic tests could be avoided.

In this prospective multicenter study with 2 years of follow-up, 165 patients with high clinical suspicion of GCA (median age, 79 years) were referred by their PCP or ophthalmologist to a physician with extensive experience in GCA diagnosis and management. Color Doppler ultrasound was performed <7 days after initiation of corticosteroid therapy. Only those patients with negative ultrasound findings underwent temporal artery biopsy (TAB). Ultrasound was considered positive if bilateral temporal halo signs were seen. Ultrasound and TAB findings were compared with physician-diagnosed GCA based on clinical findings and other imaging.

Diagnosis of GCA was confirmed in 44%, 17%, and 21% of participants by ultrasound, TAB, and clinical expertise and/or other imaging tests, respectively. Diagnosis remained unchanged at 1 month and at 2 years for those with available follow-up data. In 18% of participants, an alternative diagnosis was made. The proportion of ultrasound-positive patients among those with clinically diagnosed GCA was 54% (95% confidence interval, 45% to 62%).

Source:

Denis G, et al. (2024, May 7). Ann Intern Med. Diagnostic Strategy Using Color Doppler Ultrasound of Temporal Arteries in Patients With High Clinical Suspicion of Giant Cell Arteritis: A Prospective Cohort Study. https://pubmed.ncbi.nlm.nih.gov/38710093/

Trending icon

TRENDING THIS WEEK

EPOCRATES CME

View Catalog

view all CME activities
learn more about epocrates plus
Clinical FAQ icon

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information